EUROIMMUN expands IFA portfolio for the UNIOQ 160
EUROIMMUN (part of Revvity) has added 23 new assays to its portfolio of indirect immunofluorescence assays (IFA) for use on the UNIQO 160, its all-in-one instrument for walkway IFA automation. The new assays extend existing panels for autoantibody diagnostics in rheumatology, vasculitis, hepatology and gastroenterology.
Seven assays for autoimmune neurological diseases are also now available, introducing a new indication field for the device. With the expanded portfolio, many different autoantibodies can be investigated simultaneously, for example anti-nuclear autoantibodies (ANA), anti-neutrophil cytoplasm antibodies (ANCA), anti-mitochondrial autoantibodies (AMA), anti-smooth muscle autoantibodies (ASCA), liver-kidney-microsome (LKM) autoantibodies and neurological markers. EUROIMMUN IFA systems utilise high-quality substrates of cultured cells, antigen-expressing cells and tissue sections, which are combined into BIOCHIP Mosaics, enabling fast, reliable and comprehensive autoantibody profiling. The portfolio of assays for use on the UNIQO 160 will continue to be expanded in the future, enabling labs to maximise utilisation of their device.
The UNIQO 160 is an all-in-one solution for automation of IFA from primary sample to result proposal. It has a processing capacity of 160 samples and 18 slides per run and is therefore ideal for laboratories with medium sample throughput looking for a high degree of automation. The system offers flexible loading of controls, dilution buffers, conjugate and mounting medium. Integrated barcode scanners identify samples, reagents and slides during the entire process, ensuring quick loading, correct assignment and complete traceability of all items. The integrated high-quality microscope unit has an automatic focus and three automatically changing objectives (4x, 10x, 20x), ensuring acquisition of brilliant fluorescence images.
Result proposals are generated using the EUROPattern Classifier software, a state-of-the-art IFA evaluation software which has been trained during development using AI processes. The software uses deep convolutional neural networks to reliably differentiate positive and negative results, classify fluorescence patterns and generate titer suggestions. The EUROPattern Classifier is connected to the EUROPattern 4.0 laboratory management software, which provides complete and fully traceable administration of patient data, analyses and results.
